Biotech Karyopharm Therapeutics ($KPTI) has signed a deal with Veristat, recruiting the CRO to serve as a preferred partner as it develops a pipeline of first-in-class oncology treatments.
Under the deal, Veristat will lend its statistical consulting and biometrics services, assisting in study design, analysis and data presentation. The agreement covers Karyopharm's programs in blood cancers, glioblastoma, gynecological malignancies, prostate cancer and squamous cell carcinomas, the pair said.
"We sought a strategic partner and teammate for our programs who understands the therapeutic and regulatory aspects of our multiple trials with our novel nuclear export inhibitor Selinexor," Karyopharm CEO Sharon Shacham said in a statement. "We believe that we have found an important partner for Karyopharm given Veristat's depth of experience in oncology and with novel therapeutics."
For Karyopharm, the pairing follows its April agreement with Clinipace, another preferred-provider arrangement tasking the CRO with managing undisclosed studies in oncology, wound healing and other major diseases.
Veristat's latest deal follows a collaboration with Verastem ($VSTM) on a trial of defactinib, an in-development drug designed to treat malignant pleural mesothelioma, and a work with Aegerion Pharmaceuticals that led to the FDA approval of Juxtapid for high cholesterol.
- read the announcement